Results 81 to 90 of about 18,162 (243)
Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
Терапевтический архив, 2010 The paper gives the results of the largest international studies demonstrating the efficacy and safety of Raltegravir as part of antiretroviral treatment (ARVT) regimens in both patients starting therapy (STARTMRK study) and those pretreated with ...
Aleksey Viktorovich Kravchenko +1 more
doaj
Infectious Disease Reports, 2017 We conducted a retrospective study in a general hospital in Buenos Aires, Argentina (2009-2015) aimed at evaluating outcomes in HIV-infected pregnant women (HIPW), who were prescribed raltegravir (RAL)- containing antiretroviral therapy (ART). A total of
Diego M. Cecchini +3 more
doaj +1 more source
Cytopenias With HIV in the Era of Highly Active Antiretroviral Therapy: Are We Winning the Battle?
Health Science Reports, Volume 9, Issue 3, March 2026.ABSTRACT Background and Aim Cytopenias remain among the most frequent hematologic complications of HIV infection, affecting treatment outcomes and quality of life. The introduction of highly active antiretroviral therapy has markedly reduced their incidence by restoring immune function and suppressing viral replication.
Emmanuel Ifeanyi Obeagu
wiley +1 more source
Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]
, 2019 Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre +3 more
core +1 more source
Once‐daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post‐exposure prophylaxis following sexual exposure [PDF]
, 2020 SP Quah +4 more
openalex +1 more source
Journal of Medical Virology, Volume 98, Issue 3, March 2026.ABSTRACT The current highly active antiretroviral therapy (HAART or ART) effectively suppresses de novo HIV‐1 infection but fails to eliminate HIV reservoir cells, which leads to rapid viral rebound upon ART cessation. Chimeric antigen receptor (CAR) T cells engineered to target HIV‐1 Env⁺ cells offer a promising strategy to eliminate or control these ...
Yaoxian Lou +9 more
wiley +1 more source
Clinical Epidemiology, 2010 Frederik N Engsig1, Jan Gerstoft1, Gitte Kronborg2, Carsten S Larsen3, Gitte Pedersen4, Anne M Audelin5, Louise B Jørgensen5, Niels Obel11Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; 2Department ...
Frederik N Engsig +3 more
doaj
Raltegravir: molecular basis of its mechanism of action
European Journal of Medical Research, 2009 Integration of the HIV-1 viral DNA generated by reverse transcription of the RNA genome into the host cell chromosomes is a key step of viral replication, catalyzed by the viral integrase.
Mouscadet Jean-François +1 more
doaj +1 more source
eJHaem, Volume 7, Issue 1, February 2026.ABSTRACT Background Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy. New treatment options are urgently needed. Methods We describe a 60‐year‐old HIV‐positive patient with refractory and secondary primary BL after frontline and salvage therapy failure, treated off‐label with glofitamab successfully.
Bozzotto Elisa +7 more
wiley +1 more source
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
Viruses, 2015 Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-naïve individuals can be confronted with the problem of ...
Thibault Mesplède, Mark A. Wainberg
doaj +1 more source